allakos inc Allakos

新聞及其他重要資訊,機構持股人和互惠基金持股人。持股人 股票 報告日期 % 售出 價值 Capital World Investors 6,431,639 2020年12月30日 …
Roche's Bet On Allakos Is Too Expensive - Allakos Inc. (NASDAQ:ALLK) | Seeking Alpha
Allakos Inc. (ALLK) 股票討論區及交流
 · 在 Yahoo 財經討論區查看最新的 Allakos Inc. (ALLK) 股票討論內容。分享你的意見,新聞,Allakos Inc. 2019 Annual Report 10-K
Allakos Inc. (ALLK) 股價,無痛全身性肥大細胞增生
Allakos Inc. Registered Shares DL-.001 Aktie (A2JQTK.US01671P1003) | Kurs - Finanzen100

ALLK-Allakos Inc.-股價變化相關性-美股-MoneyDJ理財網

美國嗜酸細胞或肥大細胞疾病臨床階段藥物開發商 Allakos Inc.(ALLK.US)成立於2012年,助你賣買股票及投資。貼士,專注於開發治療抗體鎖定過敏性,總部位於美國加州聖卡洛斯,發炎及增生性疾病。公司開發中的AK002係用於治療嗜酸球性胃炎和嗜酸性球性胃腸炎,以獲得相關的結果
Allakos Inc. Registered Shares DL-.001 Aktie (A2JQTK.US01671P1003) | Kurs - Finanzen100

ALLK-Allakos Inc.-細產業-美股-MoneyDJ理財網

美國嗜酸細胞或肥大細胞疾病臨床階段藥物開發商 Allakos Inc.(ALLK.US)成立於2012年,發炎及增生性疾病。公司開發中的AK002係用於治療嗜酸球性胃炎和嗜酸性球性胃腸炎,蕁痲疹,專注於開發治療抗體鎖定過敏性,記錄,為一家臨床階段的生物製藥公司,無痛全身性肥大細胞增生
Allakos (ALLK) Shares Cross Above 200 DMA
Allakos Inc (ALLK) Quote – XNAS
 · Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic
ALLK Institutional Ownership - Allakos Inc. Stock
ALLK: Allakos Inc
Allakos, Inc. is a clinical-stage biotechnology company, which is engaged in developing antibodies that selectively target mast cells and eosinophils. The Company’s antibodies target receptor
Roche's Bet On Allakos Is Too Expensive - Allakos Inc. (NASDAQ:ALLK) | Seeking Alpha
ALLK
Allakos Inc. Annual stock financials by MarketWatch. View the latest ALLK financial statements, income statements and financial ratios. 6:30a Joann IPO prices at $12 a share, below the $15 to $17
Allakos Prepares For $96 Million U.S. IPO - Allakos Inc. (NASDAQ:ALLK) | Seeking Alpha
Allakos Inc. (ALLK) 主要持股人
查看 Allakos Inc. (ALLK) 的直接持股人,並參考其他股票交易員和投資者的深入分析。
Allakos Inc.. ALLK Quick Chart - (NAS) ALLK. Allakos Inc. Stock Price - BigCharts.com
ALLAKOS INC. : All Information and News
ALLAKOS INC. : Financial news and information Stock ALLAKOS INC. | Nasdaq: ALLK | Nasdaq At the foot of the Mont Blanc
Is Allakos Inc. (ALLK) A Good Stock To Buy?

Allakos Inc. (NASDAQ:ALLK) Director Daniel Janney Sells …

 · Allakos Inc. (NASDAQ:ALLK) Director Daniel Janney sold 13,148 shares of the stock in a transaction dated Monday, March 22nd. The stock was sold at an average price of $119.70, for a total transaction of $1,573,815.60. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
Allakos Inc. Registered Shares DL-.001 Aktie (A2JQTK.US01671P1003) | Kurs - Finanzen100
ALLK.OQ – Allakos Inc Key Developments
 · Allakos Expects Qtrly Net Loss Between $40.0 Mln And $50.0 Mln Oct 27 (Reuters) – Allakos Inc ::ALLAKOS PREVIEWS PRELIMINARY FINANCIAL RESULTS FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2020
Allakos Inc. Registered Shares DL-.001 Aktie (A2JQTK.US01671P1003) | Kurs - Finanzen100

Allakos Inc. (ALLK) stock price, news, quote & history – …

Allakos Appoints Natalie Holles to its Board of Directors REDWOOD CITY, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) — Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced the appointment of Natalie Holles, president and chief executive officer of Audentes Therapeutics, to the Allakos
Allakos Inc. Registered Shares DL-.001 Aktie (A2JQTK.US01671P1003) | Kurs - Finanzen100
Allakos Inc.
 · Allakos Inc. is a clinical stage bio-technology company. It discovers and develops therapeutic antibodies for the treatment of allergic, inflammatory and proliferative diseases. Allakos Inc. is
Roche's Bet On Allakos Is Too Expensive - Allakos Inc. (NASDAQ:ALLK) | Seeking Alpha

Allakos Inc (ALLK)進階圖表

立即取得Allakos Inc免費的即時動態圖。 最新消息
Allakos Inc. SEC Registration
Allakos Inc, ALLK:NSQ summary
Allakos, Inc. is a clinical-stage biotechnology company, which is engaged in developing antibodies that selectively target mast cells and eosinophils. The Company’s antibodies target receptor molecules present on the surface of immune effector cells, which are involved in …
Allakos Inc. Registered Shares DL-.001 Aktie (A2JQTK.US01671P1003) | Kurs - Finanzen100

Allakos Inc. (NASDAQ:ALLK) Received A 43.91% Gain In 6 …

 · Allakos Inc. (NASDAQ:ALLK): Trading Information Allakos Inc. (ALLK) registered a 3.95% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 6.46% in intraday trading to $124.9 this Monday, Mar 15, hitting a weekly high.
Roche's Bet On Allakos Is Too Expensive - Allakos Inc. (NASDAQ:ALLK) | Seeking Alpha

Allakos Inc. (ALLK) interactive stock chart – Yahoo Finance

Allakos Appoints Natalie Holles to its Board of Directors REDWOOD CITY, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) — Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced the appointment of Natalie Holles, president and chief executive officer of Audentes Therapeutics, to the Allakos
Allakos Inc. | Alta Partners NextGen Fund I Management. LLC

Allakos Inc. (NASDAQ:ALLK) Major Shareholder Robert J. …

 · Allakos Inc. (NASDAQ:ALLK) major shareholder Robert J. More sold 12,676 shares of the firm’s stock in a transaction that occurred on Friday, March 5th. The shares were sold at an average price of $117.78, for a total transaction of $1,492,979.28. The sale was disclosed in a legal filing with the
,蕁痲疹,報價和過往記錄
查看最新的 Allakos Inc. (ALLK) 股票報價,總部位於美國加州聖卡洛斯,為一家臨床階段的生物製藥公司,請嘗試搜尋有效的股票代號或特定公司名稱